Neoplasms (Oncology)

At Hôpital Européen Georges‑Pompidou the oncology unit conducts a broad portfolio of studies focused on solid tumors, evaluating novel systemic agents, immunotherapy combinations, and precision‑medicine approaches to improve survival and disease‑free outcomes.

  • Adjuvant checkpoint inhibitor therapy after complete resection of lung cancer
  • Dual‑immune checkpoint blockade versus standard surveillance in renal cell carcinoma
  • Targeted ROS1 inhibitor efficacy in advanced non‑small cell lung cancer
  • PARP inhibition combined with androgen deprivation in metastatic castration‑resistant prostate cancer
  • Weekly dose‑dense carboplatin‑paclitaxel regimen for high‑risk ovarian cancer

The site supports 40 active trials led by 25 investigators, aiming to bring cutting‑edge cancer therapies to French patients.

Respiratory Tract Diseases

Research on pulmonary conditions includes interstitial lung disease, sarcoidosis, and idiopathic pulmonary fibrosis, with trials testing anti‑inflammatory biologics and novel antifibrotic agents to preserve lung function.

  • Rituximab versus placebo for progressive interstitial lung disease
  • OATD‑01 impact on granulomatous inflammation in active pulmonary sarcoidosis
  • CAL101 evaluation of forced vital capacity in idiopathic pulmonary fibrosis
  • MTX‑463 effect on lung function decline in fibrotic lung disease

These studies reflect the department’s commitment to advancing therapeutic options for patients with chronic respiratory disorders.

Immune System Diseases

The center investigates autoimmune vasculitis and related renal complications, seeking strategies to modulate immune suppression while minimizing adverse events.

  • Immunosuppression withdrawal versus maintenance in ANCA‑associated vasculitis with end‑stage renal disease
  • Dose individualization of fluoropyrimidines based on DPD deficiency
  • Safety of sodium valproate for hearing preservation in Wolfram syndrome

By integrating biomarker‑driven dosing and targeted immunomodulation, the trials aim to improve quality of life for patients with complex immune disorders.

Cardiovascular Diseases

Clinical investigations address acute coronary events and arrhythmias, evaluating anticoagulation management technologies and novel therapeutic regimens to reduce thrombotic risk.

  • Implantable monitoring device versus standard care for anticoagulation in acute coronary syndrome with new‑onset atrial fibrillation
  • Comparative safety of antiplatelet strategies in patients with recent myocardial infarction

These projects underscore the hospital’s interdisciplinary approach to cardiovascular health, blending cardiology expertise with advanced trial design.

Digestive System Diseases

A series of gastrointestinal oncology trials explore chemotherapy optimization, biologic combinations, and molecularly guided therapies for colorectal, gastric, pancreatic, and anal cancers.

  • Modified DCF induction followed by chemoradiotherapy for locally advanced anal squamous cell carcinoma
  • FOLFOX with or without docetaxel in first‑line treatment of metastatic oesophago‑gastric adenocarcinoma
  • Pembrolizumab plus XELOX or FOLFOX and bevacizumab in microsatellite‑stable colorectal cancer with high immune infiltrate
  • Circulating tumor DNA‑guided adjuvant therapy decision in stage II colon cancer
  • Hyperthermic intraperitoneal chemotherapy (HIPEC) versus standard surgery for ovarian cancer relapse

The oncology program leverages molecular profiling and innovative drug combinations to enhance outcomes across a spectrum of digestive malignancies.